{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Etanercept", "query": { "intervention": "Etanercept" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 167, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Etanercept&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-01T23:48:10.953Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01597245", "title": "A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "80 mg ixekizumab Dosing Regimen", "type": "DRUG" }, { "name": "50 mg etanercept", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1224, "start_date": "2012-05-18", "completion_date": "2019-06-18", "has_results": true, "last_update_posted_date": "2020-06-26", "last_synced_at": "2026-09-01T23:48:10.953Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Riverside", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01597245" }, { "nct_id": "NCT02346240", "title": "Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis", "Plaque Psoriasis" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" }, { "name": "Etanercept", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 559, "start_date": "2015-02-11", "completion_date": "2018-12-17", "has_results": true, "last_update_posted_date": "2021-07-16", "last_synced_at": "2026-09-01T23:48:10.953Z", "location_count": 19, "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02346240" }, { "nct_id": "NCT00841789", "title": "A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mucocutaneous Lymph Node Syndrome", "Kawasaki Disease" ], "interventions": [ { "name": "Etanercept", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael Portman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Months", "maximum_age": "20 Years", "sex": "ALL", "summary": "2 Months to 20 Years" }, "enrollment_count": 205, "start_date": "2009-03", "completion_date": "2018-08-30", "has_results": true, "last_update_posted_date": "2023-05-06", "last_synced_at": "2026-09-01T23:48:10.953Z", "location_count": 7, "location_summary": "New Hyde Park, New York • New York, New York • The Bronx, New York + 4 more", "locations": [ { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00841789" }, { "nct_id": "NCT01030120", "title": "Etanercept for the Treatment of Chronic Urticaria", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Chronic Idiopathic Urticaria" ], "interventions": [ { "name": "etanercept", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2010-12", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2015-06-02", "last_synced_at": "2026-09-01T23:48:10.953Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01030120" }, { "nct_id": "NCT00134394", "title": "Etanercept With Tacrolimus for Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Etanercept plus tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2005-02", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2008-08-07", "last_synced_at": "2026-09-01T23:48:10.953Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00134394" }, { "nct_id": "NCT00201812", "title": "Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors" ], "interventions": [ { "name": "Etanercept", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2000-11", "completion_date": "2005-05", "has_results": false, "last_update_posted_date": "2017-12-06", "last_synced_at": "2026-09-01T23:48:10.953Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00201812" }, { "nct_id": "NCT02862574", "title": "Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Andecaliximab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "TNF Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 15, "start_date": "2016-12-15", "completion_date": "2017-08-07", "has_results": true, "last_update_posted_date": "2018-06-27", "last_synced_at": "2026-09-01T23:48:10.953Z", "location_count": 8, "location_summary": "Palo Alto, California • DeBary, Florida • Las Vegas, Nevada + 5 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "DeBary", "state": "Florida" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT02862574" }, { "nct_id": "NCT01004432", "title": "Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis", "Arthritis, Rheumatoid", "Autoimmune Diseases" ], "interventions": [ { "name": "Golimumab 50 mg SC", "type": "DRUG" }, { "name": "Golimumab 2 mg/kg IV", "type": "DRUG" }, { "name": "Methotrexate (MTX)", "type": "DRUG" }, { "name": "Placebo SC", "type": "DRUG" }, { "name": "Placebo IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 433, "start_date": "2009-12", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-09-01T23:48:10.953Z", "location_count": 89, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 86 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01004432" }, { "nct_id": "NCT00000433", "title": "Blocking Tumor Necrosis Factor in Ankylosing Spondylitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Spondylitis, Ankylosing" ], "interventions": [ { "name": "Anti-Tumor Necrosis Factor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 42, "start_date": "1999-10", "completion_date": "2002-03", "has_results": false, "last_update_posted_date": "2007-01-04", "last_synced_at": "2026-09-01T23:48:10.953Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000433" }, { "nct_id": "NCT01690299", "title": "Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis", "Psoriatic Arthritis" ], "interventions": [ { "name": "Apremilast", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Placebo tablet", "type": "DRUG" }, { "name": "Placebo injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2012-10-01", "completion_date": "2016-04-04", "has_results": true, "last_update_posted_date": "2022-03-15", "last_synced_at": "2026-09-01T23:48:10.953Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Bakersfield, California • Irvine, California + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01690299" } ] }